Bristol-Myers Squibb Company Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting

Published: May 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Bristol-Myers Squibb Company (NYSE: BMY) today announced that new data on its approved and investigational immuno-oncology compounds, Yervoy and the investigational PD-1 receptor blocking antibody nivolumab, will be featured in six oral presentations at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 - June 4.

Help employers find you! Check out all the jobs and post your resume.

Back to news